Biosynthesis of rose aroma

By expressing the mevalonate pathway and Nudix pathway genes in host cells, the efficient biosynthesis of geraniol and geraniol acetate was achieved, solving the problem of insufficient yield of the biotechnology route in the prior art, and providing a sustainable and environmentally friendly production methods.

CN118922529APending Publication Date: 2024-11-08AGENCY FOR SCI TECH & RES
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380026279.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-07
Filing Date
2023-03-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, geraniol and geraniol acetate are mainly produced through chemical synthesis, and the solubility and activity of plant geraniol synthase used in the biotechnology route in microorganisms is insufficient, which limits the yield of geraniol and cannot Meet the demand for natural ingredients.

Method used

Using vectors containing the mevalonate pathway and Nudix pathway genes, the biogenes of geraniol and geraniacetate are performed by expressing relevant enzymes in host cells, including diphosphate synthase, isoprene transferase and geraniyl synthase. synthesis.

Benefits of technology

Improves the yields of geraniol and geraniacetate, meets the demand for natural ingredients, and provides a sustainable and environmentally friendly production method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005033352900000261
    Figure BDA0005033352900000261
  • Figure BDA0005033352900000271
    Figure BDA0005033352900000271
  • Figure BDA0005033352900000272
    Figure BDA0005033352900000272
Patent Text Reader

Abstract

The present application relates to a host cell comprising a first vector comprising a polynucleotide sequence encoding a mevalonate pathway gene and a second vector comprising a polynucleotide sequence encoding a geraniol diphosphate synthase (GP-PS) and a Nudix hydrolase. In embodiments, the host cell is an Escherichia coli cell, and the mevalonate pathway genes are HMG-CoA synthase (hmgS), acetoacetyl-CoA thiolase (afoB), HMG-CoA reductase (hmgR), mevalonate kinase (mevK), phosphomevalonate kinase (pik), mevalonate pyrophosphate decarboxylase (pmd), and (isopentenyl diphosphate) IPP isomerase ( / d / ); gPPS is Escherichia coli IspA (ispAS80F) containing S80F mutation, and GPPS is Escherichia coli IspA ( And the Nudix hydrolase is RhNUDXI separated from the modern Chinese rose. Also disclosed are methods and kits for producing geraniol and geranyl acetate, comprising culturing the host cells thereof. In addition, the invention also discloses an engineering fusion protein containing the RhNUDXI and the ispAS80F.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to Singapore application number 10202251656V filed on November 7, 2022 and Singapore application number 10202202455U filed on March 10, 2022, the entire contents of which are hereby incorporated by reference in their entirety for all purposes. Technical Field

[0003] The present invention relates to the biosynthesis of terpenoid compounds, in particular rose aroma molecules. Background Art

[0004] Rose oil is rich in volatile molecules, among which monoterpenes play a vital role in the characteristic rose smell. Geraniol, a monoterpene alcohol with rose-like odor and taste, is an important commercial flavor and fragrance molecule. Geraniol and its ester derivative, geranyl acetate, are the two most important monoterpenes in rose oil. Geraniol is widely used in deodorants, perfumes, and beauty creams. It is also an effective plant-based mosquito repellent and insecticide with low mammalian toxicity and biodegradability. The ester derivative of geraniol, geranyl acetate, is widely used in the cosmetics industry for its floral and fruity aroma.

[0005] However, these molecules are only produced in low concentrations in plants. At present, geraniol and geranyl acetate are mainly produced by chemical synthesis, which is unsustainable and not environmentally friendly. In addition, consumers' demand for natural ingredients or biological ingredients is increasing. Therefore, there is increasing interest in developing biotechnological routes for producing geraniol and geranyl acetate, and in recent years, biotechnological routes for producing geraniol have been developed. Most of these routes use plant geraniol synthase (GES), which has insufficient solubility and / or activity in microorganisms, thereby limiting the yield of geraniol. Therefore, it is necessary to provide a method and system for the biosynthesis of geraniol and geranyl acetate that overcomes or at least improves one or more of the above-mentioned shortcomings. Summary of the invention

[0006] In one aspect, provided herein is a host cell comprising one or more vectors comprising a polynucleotide sequence encoding one or more genes of the mevalonate pathway and one or more genes of the Nudix pathway.

[0007] In another aspect, the present invention provides an engineered fusion protein comprising a diphosphate synthase or prenyltransferase of the mevalonate pathway, and a Nudix hydrolase; or a diphosphate synthase or prenyltransferase of the mevalonate pathway, a Nudix hydrolase, and a geranyl synthase (GES) of the terpene synthase pathway; or a diphosphate synthase or prenyltransferase of the mevalonate pathway and a GES of the terpene synthase pathway.

[0008] In another aspect, provided herein is a method for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, comprising culturing a host cell described herein in a culture medium, wherein the culture medium comprises an inducing agent and at least one carbon substrate.

[0009] In another aspect, provided herein is a kit for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, wherein the kit comprises a host cell described herein and instructions for use.

[0010] definition

[0011] As used herein, the term "isoprenoid" refers to a large and diverse class of naturally occurring organic compounds composed of two or more hydrocarbon units, each consisting of five carbon atoms arranged in a specific pattern.

[0012] The term "monoterpenes" or "monoterpenoids" as used herein refers to a class of isoprenoids produced from geranyl diphosphate by various monoterpene synthases. Monoterpenes have two isoprenoid units. Monoterpenes are secondary metabolites of plants and are the main components of essential oils, cosmetics, food flavorings, cleaning products and pharmaceuticals. They provide the specific odor characteristics of plants. Monoterpenes are used industrially as flavors, fragrances and cosmetic ingredients. In addition, they are precursors to several flavor compounds such as citronellol, geraniol, menthol and verbenol.

[0013] As used herein, the term "mevalonate pathway" refers to a cellular metabolic pathway that plays a key role in multiple cellular processes by synthesizing sterol isoprenoids such as cholesterol and polystyrene, heme A, isopentenyl tRNA, and non-sterol isoprenoids such as ubiquinone. The mevalonate pathway is the first recognized biosynthetic pathway for isopentenylpyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), and it involves a series of six enzymatic steps that convert acetyl-CoA to IPP. In the first two steps of the mevalonate pathway, three acetyl-CoA molecules are condensed to synthesize mevalonate. Acetoacetyl-CoA thiolase and HMG-CoA synthase (HMGS) catalyze the condensation reaction to form hydroxymethylglutaryl-CoA (HMG-CoA). Furthermore, HMG-CoA reductase (HMGR) catalyzes the reduction of HMG-CoA to mevalonate. The synthesized mevalonate is thus phosphorylated and decarboxylated to form IPP. Phosphorylation is first catalyzed by mevalonate kinase, followed by the formation of mevalonate-5-pyrophosphate under the action of phosphomevalonate kinase (PMK). Decarboxylation is the last step, in which phosphomevalonate decarboxylase catalyzes the ATP-dependent decarboxylation of mevalonate-5-pyrophosphate to form IPP. IPP can interact with DHNA to form AQ, or with isomerases to form DMAPP via IPP isomerase (IDI). Mevalonate pathway genes refer to genes encoding enzymes of the mevalonate pathway.

[0014] As used herein, the term "Nudix hydrolase" refers to a superfamily of hydrolases and is found in all classes of organisms. Nudix hydrolases hydrolyze a variety of organic pyrophosphates with varying degrees of substrate specificity, including nucleoside diphosphates and triphosphates, dinucleosides and diphosphate inositol polyphosphates, nucleotide sugars, and RNA caps.

[0015] The term "Nudix pathway" as used herein refers to a metabolic pathway involving diphosphohydrolases belonging to the Nudix enzyme family. Nudix hydrolases (e.g., AtNUDX1, NudI, RhNUDX1) in the cytoplasm convert geranyl diphosphate (GPP) to geranyl monophosphate (GP), which is then hydrolyzed to geraniol by phosphatase activity. Nudix pathway genes refer to genes encoding Nudix pathway enzymes.

[0016] The term "geraniol" as used herein refers to a compound of formula C 10 H 18 O is an acyclic monoterpene alcohol of 3,7-dimethyl-2,6-octen-1-ol. Geraniol can be produced by aromatic plants. Geraniol can also be biosynthesized in engineered strains, including Saccharomyces cerevisiae.

[0017] The term "geranyl acetate" as used herein is a monoterpene that is the acetate derivative of geraniol.

[0018] The term "polypeptide" as used herein includes polypeptides, proteins, peptides, polypeptide fragments and fusion polypeptides.

[0019] As used herein, "nucleic acid" refers to two or more deoxyribonucleotides and / or ribonucleotides covalently linked together in either single-stranded or double-stranded form.

[0020] As used herein, the term "operably linked" refers to a functional connection between a nucleic acid expression control sequence (eg, a promoter) and a second nucleic acid sequence, wherein the expression control sequence regulates the transcription of the nucleic acid corresponding to the second sequence.

[0021] The term "variant" as used herein refers to a modification in a DNA sequence. Modifications of the DNA sequence include mutation, truncation, translocation, substitution, deletion and insertion, which result in changes in gene activity.

[0022] The term "promoter" as used herein refers to a DNA region that initiates gene transcription. This DNA region is usually located near the gene transcription start site and upstream of the DNA. A promoter can be inducible or non-inducible. The term "inducible promoter" as used herein refers to a promoter that can be regulated in response to a specific stimulus (also referred to as an inducer). The promoter system can be inducible after modification. Examples of inducible promoter systems include Tet-on system, Tet-off system, T7 system, Trp system, Tac system, λcI857-PL system, bacterial EL222 system and Lac system. A promoter can also be a constitutive promoter, which is a promoter that is always active.

[0023] The term "ribosome binding site" as used herein in the context of this application refers to the site of an mRNA molecule that recruits and binds to a ribosome, thereby allowing selection of an appropriate start codon during translation initiation. The ribosome binding site controls the accuracy and efficiency of mRNA translation initiation.

[0024] As used herein, the term "linker" refers to a short amino acid sequence that separates multiple domains in a recombinant protein or fusion protein. The function of a linker is to inhibit unwanted interactions between discrete domains. However, there are some flexible Gly-rich linkers that can connect various domains in a single protein without interfering with the function of each domain. Gly-rich linkers can also help to establish covalent links between proteins to form stable protein-protein complexes. The length of the linker varies from 2-31 amino acids and is optimized for each condition, so that the linker does not impose any restrictions on the conformation or interaction of the linked partners. .

[0025] As used herein, the term "lack / deficiency" in the context of gene or protein expression refers to a decrease in the expression level of a gene or protein relative to the baseline expression level of the gene or protein. In the context of gene or protein expression, lack / deficiency may also refer to the absence of expression of a gene or protein when the gene or protein is otherwise expressed. Baseline expression of a gene or protein should be understood to refer to the expression level of a non-mutated gene or wild-type gene, or to the expression level of a gene or protein when the gene or protein would otherwise be expressed.

[0026] As used herein, the term "coexpression" refers to the transcription and / or translation of two or more genes as a single unit. The transcription and / or translation of two or more genes as a single unit can occur via the fusion of two or more genes. Alternatively, in the context of gene and / or protein expression, coexpression can also refer to the transcription and / or translation of two or more genes as separate units.

[0027] As used herein, the term "about", in the context of component concentrations and compound percentages (but not limited thereto), typically refers to + / -10% of the value, + / -9% of the value, + / -8% of the value, + / -7% of the value, + / -6% of the value, + / -5% of the value, + / -4% of the value, more typically refers to + / -3% of the value, more typically refers to + / -2% of the value, even more typically refers to + / -1% of the value, and even more typically refers to + / -0.5% of the value. Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of a range should be considered to have specifically disclosed all possible subranges and individual values ​​within the range. For example, description of a range of 1-6 etc. should be considered to have specifically disclosed subranges within that range of 1-3, 1-4, 1-5, 2-4, 2-6, 3-6 etc., as well as individual numbers 1, 2, 3, 4, 5, and 6 etc. This applies no matter how large the range is.

[0028] BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and accompanying drawings, in which:

[0030] Figure 1 The biosynthetic pathways of geraniol and geranyl acetate are depicted. The biosynthetic pathway consists of the following: 1) mevalonate pathway genes, including atoB, hmgS and thmgR, mevk, pmk, pmd, and idi; 2) monoterpene pathway genes, including GPPS, RhNUDX1, phosphatases, and RhAAT1; 3) other genes: yjgB. Abbreviations of compounds: MVA, mevalonate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; GPP, geranyl pyrophosphate; GP, geranyl phosphate. Dashed arrows indicate multiple enzymatic steps. The expressed genes encode the following enzymes: GPPS, GPP synthase; RhNUDX1, a Nudix hydrolase from modern rose (Rosa hybrida); RhAAT1, an alcohol acyltransferase from modern rose, catalyzing geraniol to geranyl acetate; yjgB, an alcohol dehydrogenase that converts geraniol to geranaldehyde.

[0031] Figure 2 In vitro characterization and in vivo application of RhNUDX1 are shown. Figure 2 Figure A shows the characterization of purified RhNUDX1 (K calculated in Table 5 m and k cat ). Figure 2 Panel B depicts a study of the effect of pH on RhNUDX1. Figure 2 Panel C shows in vivo application of RhNUDX1 to produce geraniol. Figure 2 D shows the OD of different strains 600 Error bars, mean ± sd, n = 4-7.

[0032] Figure 3 Enhanced GPP supply and pathway balance are depicted. Figure 3 A in Figure 2 shows the monoterpene titer. Figure 3 B shows the OD of the strain constructed by combining RBS engineering and GPPS screening. 600 . Figure 3 C in the figure shows the geraniol titer, Figure 3 D in the figure depicts the OD of the strain constructed by pathway balance. 600 Error bars, mean ± sd, n = 3-6.

[0033] Figure 4Fusion of GPPS with RhNUDX1 is shown. (A) Monoterpene titers and OD in strains with fused and free forms of GPPS and RhNUDX1 600 .

[0034] Figure 5 Deletion of YjgB is depicted. (A) Monoterpene titers and (B) OD in wild-type (WT) and mutant (ΔyjgB) strains. 600 .

[0035] Figure 6 Refers to abiotic strategies that minimize by-product formation. Figure 6 Panel A shows the GC of chemical standards as well as chromatograms of optimized (40 mM lactose) and control (20 mM lactose) conditions. Figure 6 Figure B depicts monoterpene production and OD in autoinduction defined medium with adjusted lactose dosage. 600 . Figure 6 C shows the monoterpene production and OD in the manually induced defined medium with adjusted IPTG dosage. 600 Error bars, mean ± sd, n = 2-3.

[0036] Figure 7 Comparison of GES, RhNUDX1, NudI and their combination with ispA, AgGPPS is shown. Figure 7 A in FIG. 2 shows the geraniol production of the strains using various enzymes. Figure 7 B shows the OD of the strain 600 . Figure 7 C shows the geraniol production of the strain using the combination of GES / Nudix enzymes with additional GPPS, Figure 7 D in the figure shows the OD of the strain 600 Error bars, mean ± SD, n = 2.

[0037] Figure 8 Refers to the optimization of the biological production of geraniol acetate. Figure 8 A shows the geraniol titer and OD of the strain constructed by pathway balance. 600 . Figure 8 Panel B shows the optimization of induction of the two best geranyl acetate strains. Error bars, mean ± SD, n = 3.

[0038] Fig. 9 Refers to the fed-batch fermentation of geraniol and geranyl acetate. Fig. 9 A in Figure 2 shows geraniol and OD 600 Time course curve. Fig. 9 B shows geranyl acetate and OD 600 Time course curve.

[0039] Fig.10 The effect of the deletion of ackA-pta on geranyl acetate production is shown. The glycerol concentration in the medium was 20 g / L or 30 g / L. Here, "-" refers to the strain without the ackA-pta deletion. The cells were grown in 10 mL of TB medium in a 125 mL baffled flask at 100 rpm and 28C for 3 days.

[0040] Fig.11 Depicted is the effect of tryptone supplementation on geraniol biosynthesis. Error bars, mean ± sd, n = 2. Cells were grown in vitro in 1 mL chemically defined medium at 300 rpm, 28°C for 3 days.

[0041] Fig.12 Optimization of the dodecane / medium ratio is shown. Error bars, mean ± sd, n = 2. Cells were grown in 10 mL of chemically defined medium in 125 mL baffled flasks at 100 rpm, 28°C for 3 days.

[0042] Fig.13 The enzyme combinations used in this study are described. DETAILED DESCRIPTION

[0043] In a first aspect, the invention relates to a host cell comprising one or more vectors comprising a polynucleotide sequence encoding: a) one or more genes of the mevalonate pathway, and b) one or more genes of the Nudix pathway.

[0044] One or more genes of the mevalonate pathway and one or more genes of the Nudix pathway can be encoded on one or more vectors in the host cell. For example, the polynucleotide sequence can be encoded on one vector, two vectors, three vectors, four vectors, five vectors, or six vectors. It will be appreciated by those skilled in the art that one or more genes of the mevalonate pathway and one or more genes of the Nudix pathway can be located in one or more vectors in different combinations. In one example, one or more genes of the mevalonate pathway can be encoded on one vector, while one or more genes of the Nudix pathway can be encoded on another vector. In another example, one or more genes of the mevalonate pathway can be encoded on two vectors, while one or more genes of the Nudix pathway can be encoded on another vector. In another example, one or more genes of the Nudix pathway can be encoded on two vectors, while one or more genes of the mevalonate pathway can be encoded on another vector. It will also be appreciated by those skilled in the art that in the case where there is more than one gene in one pathway, these genes can be encoded in combination with one or more genes of another pathway on a separate vector. It will generally be appreciated that the examples provided above are not exhaustive, and different combinations are acceptable.

[0045] One or more genes of the mevalonate pathway and one or more genes of the Nudix pathway can be inserted into the genome of the host cell in some instances. It should be understood by those skilled in the art that the genomic insertion of one or more genes of the mevalonate pathway and one or more genes of the Nudix pathway into the host genome refers to the targeted and stable insertion of exogenous genes into the host genome, thereby allowing stable gene expression. One or more genes of the mevalonate pathway and one or more genes of the Nudix pathway can be inserted into the genome of the host cell using genomic modification methods, including but not limited to CRISPR-Cas9, TALEN-mediated gene knock-in.

[0046] In one example, the host cell can contain two vectors, wherein a) the first vector contains a polynucleotide sequence encoding one or more genes of the mevalonate pathway; and b) the second vector contains a polynucleotide sequence encoding one or more genes of the Nudix pathway.

[0047] Genes of the mevalonate pathway include, but are not limited to, HMG-CoA synthase (hmgS), acetoacetyl-CoA thiolase (atoB), HMG-CoA reductase (hmgR), mevalonate kinase (mevK), phosphomevalonate kinase (pmk), mevalonate pyrophosphate decarboxylase (pmd), (isopentenyl diphosphate) IPP isomerase (idi), isopentenyl phosphate kinase, mevalonate 3-phosphate kinase, choline kinase, and acid phosphatase. Nudix pathway genes include, but are not limited to, NUDX1, NudI, NudA, NudB, NudC, NudH, DR2204, IalA, and MJ1149.

[0048] In some instances, one or more genes of mevalonate pathway are separated from bacteria or yeast. In one example, one or more genes of mevalonate pathway can be separated from selected from following bacteria: Escherichia coli (Escherichiacoli), Pantoea agglomerans (Pantoea agglomerans), Pantoea ananatis (Pantoea ananatis), uncultured marine bacteria HF10_19P19, Sulfolobus solfataricus (Sulfolobus solfataricus), Anabaenavariabilis (Anabaenavariabilis) and Brevundimonas sp. (Brevundimonas sp.). In one example, one or more genes of mevalonate pathway can be separated from selected from following yeast: Saccharomyces cerevisiae (Saccharomyces cerevisiae), Yarrowia lipolytica (Yarrowia lipolytica), Rhodosporidium toruloides (Rhodosporidium toruloides), Candida (Candida) and Pichia (Pichia).

[0049] In one example, one or more genes of the mevalonate pathway can be selected from HMG-CoA synthase (hmgS), acetoacetyl-CoA thiolase (atoB), HMG-CoA reductase (hmgR), mevalonate kinase (mevK), phosphomevalonate kinase (pmk), mevalonate pyrophosphate decarboxylase (pmd), (isopentenyl diphosphate) IPP isomerase (idi), or a combination thereof.

[0050] In some examples, one or more genes of the Nudix pathway are isolated from prokaryotes or plants. Prokaryotes can be bacteria or archaea. In one example, one or more genes of the Nudix pathway can be isolated from bacteria selected from Escherichia coli, Deinococcus radiodurans, and Bartonella bacilliformis. In another example, one or more genes of the Nudix pathway can be isolated from archaea such as Methanocaldococcus jannaschii. In another example, one or more genes of the Nudix pathway can be isolated from plants selected from modern roses (Rose hybrida) and Arabidopsis thaliana.

[0051] In one example, the one or more genes of the Nudix pathway can be selected from NUDX1, NudI, NudA, NudB, NudC, NudH, DR2204, Ia1A, MJ1149, or a combination thereof.

[0052] In one example, the polynucleotide sequence encoding the atoB gene is SEQ ID NO: 19. In one example, the polynucleotide sequence encoding the hmgS gene is SEQ ID NO: 20. In one example, the polynucleotide sequence encoding the mevK gene is SEQ ID NO: 21. In one example, the polynucleotide sequence encoding the pmk gene is SEQ ID NO: 22. In one example, the polynucleotide sequence encoding the pmd gene is SEQ ID NO: 23. In one example, the polynucleotide sequence encoding the idi gene is SEQ ID NO: 24. In one example, the polynucleotide sequence encoding the RhNUDX1 gene is SEQ ID NO: 25. In one example, the polynucleotide sequence encoding the NudI gene is SEQ ID NO: 26. In one example, the polypeptide sequence of hmgR is SEQ ID NO: 66.

[0053] One or more genes of the mevalonate and Nudix pathways can be modified in some instances. The modification of one or more genes can include mutation, truncation, translocation, substitution, deletion and insertion, or post-translational modification of translated genes. Genes can be modified to increase expression levels. Post-translational modification of translated proteins or any combination of these modifications.

[0054] In one example, the hmgR gene is truncated (referred to as "thmgR"). Those skilled in the art will recognize that the term "truncation" refers to the elimination of the N-terminal or C-terminal portion of the protein by manipulating the structural gene, or the premature termination of protein elongation due to the presence of a stop codon in its structural gene due to a nonsense mutation. In one example, the polypeptide sequence of the truncated hmgR is SEQ ID NO: 27, and the polynucleotide sequence encoding the truncated hmgR gene is SEQ ID NO: 28.

[0055] In some examples, one or more vectors may include a polynucleotide sequence encoding one or more diphosphate synthase genes, isopentyltransferase genes, or a combination of diphosphate synthase and isopentyltransferase genes. One or more diphosphate synthase genes, isopentyltransferase genes, or a combination of diphosphate synthase and isopentyltransferase genes may be located on the first vector or the second vector, or on both the first vector and the second vector. In one example, the polynucleotide encoding one or more diphosphate synthase genes, isopentyltransferase genes, or a combination of diphosphate synthase and isopentyltransferase genes is encoded on the second vector. Those skilled in the art will also recognize that the polynucleotide sequence on each vector may include a combination of diphosphate synthase genes or isopentyltransferase genes. For example, the polynucleotide sequence may encode a diphosphate synthase gene. In another example, the polynucleotide sequence may encode an isopentyltransferase gene. In another example, the polynucleotide sequence may encode two diphosphate synthase genes. In another example, the polynucleotide sequence may encode two isopentyltransferase genes. In yet another example, the polynucleotide sequence may encode a diphosphate synthase gene and an isopentyltransferase gene. It should generally be understood that the examples provided above are not exhaustive and different combinations are acceptable.

[0056] It should be understood that the polynucleotide sequence in one or more vectors is operably linked to a promoter. It should generally be understood that any promoter that allows expression of the polynucleotide sequence can be used. Examples of promoters include, but are not limited to, T7 RNA polymerase promoter, lac promoter, araBAD promoter, tac promoter, λcI857-PL promoter, and T5 promoter.

[0057] In some instances, the promoter can be an inducible promoter. In one instance, the promoter can be naturally inducible. In one instance, the promoter can be inducible after modification. It should be appreciated that any suitable inducible promoter system can be used. The inducible promoter system can be induced by an inducer or stimulus, including but not limited to chemical inducers, light or heat.

[0058] In one example, the polynucleotide sequence is operably linked to an inducible promoter in one or more vectors and is operably linked to a non-inducible promoter in other vectors. For example, the polynucleotide sequence is operably linked to an inducible promoter in each vector. In another example, the polynucleotide sequence is operably linked to an inducible promoter in two vectors, and the polynucleotide sequence is operably linked to a non-inducible promoter in other vectors.

[0059] In one example, the polynucleotide sequence in each vector is operably linked to an inducible promoter. In one example, the inducible promoter is a wild-type T7 RNA polymerase promoter or a variant of a wild-type T7 RNA polymerase promoter. The variant of the wild-type T7 RNA polymerase promoter can be generated via a mutation of the wild-type promoter. In another example, the T7 RNA polymerase promoter variant is selected from TM1, TM2, TM3, TV1, TV2, TV3 and TV4. In one example, the polynucleotide sequence encoding the wild-type T7 RNA polymerase promoter is SEQ ID NO:29. In one example, the polynucleotide encoding the TM1 promoter is SEQ ID NO:30. In one example, the polynucleotide encoding the TM2 promoter is SEQ ID NO:31. In one example, the polynucleotide encoding the TM3 promoter is SEQ ID NO:32. In one example, the polynucleotide sequence encoding the TV1 promoter is SEQ ID NO:33. In one example, the polynucleotide sequence encoding the TV2 promoter is SEQ ID NO:34. In one example, the polynucleotide sequence encoding the TV3 promoter is SEQ ID NO: 35. In one example, the polynucleotide sequence encoding the TV4 promoter is SEQ ID NO: 36.

[0060] The inducible promoter in each carrier can be independently selected from wild-type T7 RNA polymerase promoter or variant. In an example, the inducible promoter in each carrier can be wild-type T7 RNA polymerase promoter. In another example, the inducible promoter in each carrier can be identical T7 RNA polymerase promoter variant. In another example, the inducible promoter in each carrier can be different wild-type T7 RNA polymerase promoters and variants or their combinations. It should be generally understood that, except the example provided herein, the different combinations of inducible promoters can be used together with each carrier of the present invention.

[0061] In some examples, different combinations of inducible promoters can be used with each vector to balance genes in the mevalonate pathway, the Nudix pathway, or both the mevalonate and Nudix pathways and to optimize the expression level of each gene in the mevalonate genes or the Nudix genes.

[0062] In one example, the first vector can include a) a polynucleotide sequence operably linked to a first inducible promoter, encoding the hmgS, atoB, and hmgR genes of the mevalonate pathway; and b) a polynucleotide sequence operably linked to a second inducible promoter, encoding the mevK, pmk, pmd, and idi genes of the mevalonate pathway.

[0063] In one example, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequences encoding atoB, hmgS, and truncated hmgR genes of the mevalonate pathway is TM1, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequences encoding mevk, pmk, pmd, and idi genes of the mevalonate pathway is TM1, and the inducible promoter in the second vector of the host cell described herein comprising the polynucleotide sequence encoding the NUDX1 gene of the Nudix pathway is TM1. In one example, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequence encoding atoB, hmgS, and truncated hmgR genes of the mevalonate pathway is TM1, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequence encoding the mevalonate pathway is TM2, and the inducible promoter in the second vector of the host cell described herein comprising the polynucleotide sequence encoding the NUDX1 gene of the Nudix pathway is TM1. In one example, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequences encoding atoB, hmgS and truncated hmgR genes of the mevalonate pathway is TM2, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequences encoding mevk, pmk, pmd and idi genes of the mevalonate pathway is TM1, and the inducible promoter in the second vector of the host cell described herein comprising the polynucleotide sequence encoding the NUDX1 gene of the Nudix pathway is TM1. In a preferred example, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequence encoding atoB, hmgS and truncated hmgR genes of the mevalonate pathway is TM3, the inducible promoter in the first vector of the host cell described herein comprising the polynucleotide sequence encoding the mevk, pmk, pmd and idi genes of the mevalonate pathway is TM2, and the inducible promoter in the second vector of the host cell described herein comprising the polynucleotide sequence encoding the NUDX1 gene of the Nudix pathway is TM1. It should generally be understood that, in addition to the examples provided herein, different combinations of inducible promoters can be used with each of the vectors of the invention.

[0064] One or more vectors in the host cell described herein may also include one or more polynucleotide sequences encoding ribosomal binding sites (RBS). Each vector in the host cell may also include a polynucleotide sequence encoding RBS, or some vectors may also include a polynucleotide sequence encoding RBS, while other vectors do not. For example, each of the first and second vectors may also include a polynucleotide sequence encoding RBS. In another example, the first vector may include a polynucleotide sequence encoding RBS, while the second vector does not.

[0065] It will be appreciated by those skilled in the art that for the translation efficiency and intensity of the RBS, the sequence encoding the RBS can be optimized for the polynucleotide sequence to be translated. The optimization of the RBS should generally be understood to be related to the polynucleotide sequence of the modified RBS. The RBS can be modified by substitution, deletion, insertion or a combination thereof of one or more nucleotide bases. The RBS can be modified using degenerate oligonucleotide bases.

[0066] The polynucleotide sequence encoding the RBS can be synthesized and inserted upstream of one or more genes in one or more vectors. For example, the RBS can be synthesized and inserted upstream of two genes in two vectors. In another example, the polynucleotide sequence encoding the RBS can be synthesized and inserted upstream of a gene in one vector. It should generally be understood that the examples provided above are not exhaustive and different combinations are acceptable.

[0067] In one example, the first vector may further comprise a polynucleotide sequence encoding a ribosome binding site (RBS) located upstream of a mevalonate pathway gene.

[0068] In some examples, the RBS in the first vector can comprise a polynucleotide sequence of SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, or a combination thereof.

[0069] In one example, the second vector may further comprise a polynucleotide sequence encoding a ribosome binding site (RBS) upstream of the polynucleotide sequence encoding the diphosphate synthase gene or the isopentenyl transferase gene.

[0070] In some examples, the RBS in the second vector may comprise a polynucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or a combination thereof. In a preferred example, the RBS comprises a polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4.

[0071] The diphosphate synthase or prenyl transferase in the host cell may be selected from geranyl pyrophosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS) or geranylgeranyl pyrophosphate synthase.

[0072] In some examples, the diphosphate synthase or isopentenyl transferase in the host cell can be modified. The modification of the diphosphate synthase or isopentenyl transferase can include mutation, truncation, translocation, substitution, deletion and insertion.

[0073] In some examples, GPPS can be isolated from Mentha piperita, Arabidopsis thaliana, Abies grandis, Antirrhimum majus and Clarkia breweri. In a preferred example, GPPS is isolated from Abies grandis (AgGPPS).

[0074] In one example, AgGPPS is truncated at the N-terminus.

[0075] In one example, AgGPPS is truncated between amino acid positions 2-85. In one example, AgGPPS can be truncated from amino acid positions 2-30. In another example, AgGPPS can be truncated from amino acid positions 2-50. In another example, AgGPPS can be truncated from amino acid positions 2-80. In another example, AgGPPS can be truncated from amino acid positions 2-84. It should generally be understood that the examples provided above are not exhaustive and different combinations are acceptable. In a preferred example, AgGPPS is truncated from amino acid positions 2-85.

[0076] In one example, the truncated AgGPPS comprises the polypeptide sequence shown in SEQ ID NO:7.

[0077] In some examples, FPPS can be isolated from Saccharomyces cerevisiae, Escherichia coli, Neurosporacrassa and Gibberella fujikuroi. In a preferred example, FPPS is isolated from Saccharomyces cerevisiae or Escherichia coli.

[0078] In some examples, the FPPS can be modified. Modifications of the FPPS can include mutations, truncations, translocations, substitutions, deletions, and insertions to increase expression levels.

[0079] In one example, the serine residue at amino acid position 80 of FPPS isolated from E. coli is mutated to phenylalanine.

[0080] In one example, the mutant FPPS of E. coli comprises the polypeptide sequence shown in SEQ ID NO:9.

[0081] In one example, the FPPS is isolated from Saccharomyces cerevisiae and comprises a) an asparagine to tryptophan mutation at amino acid 127; or b) a phenylalanine to tryptophan mutation at amino acid position 96. It will be appreciated by those skilled in the art that the FPPS isolated from Saccharomyces cerevisiae comprises a combination of both mutations.

[0082] In one example, the mutant FPPS of Saccharomyces cerevisiae comprises the polypeptide sequence shown in SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:13.

[0083] One or more genes of the Nudix pathway can be isolated from eukaryotic organisms. In one example, NUDX1 of the Nudix pathway can be isolated from plants. The plant can be, but is not limited to, modern roses and Arabidopsis.

[0084] In one example, NUDX1 is isolated from a modern rose and has about 70%, 75%, 80%, 85%, 90%, 95% or 100% identity to the polypeptide sequence shown in SEQ ID NO:14.

[0085] In another example, NUDX1 is isolated from Arabidopsis thaliana and has 70%, 75%, 80%, 85%, 90%, 95% or 100% identity to the polypeptide sequence shown in SEQ ID NO:15.

[0086] One or more genes of the Nudix pathway can also be isolated from a prokaryotic organism. In one example, NudI, NudA, NudB, NudC or NudH can be isolated from a prokaryotic organism. The prokaryotic organism can be, but is not limited to, Escherichia coli, Salmonella typhi, Salmonella paratyphi B, and Cedecea neteri.

[0087] In some examples, one or more genes of the Nudix pathway can be co-expressed with a diphosphate synthase or isopentenyl transferase gene. In one example, one or more genes of the Nudix pathway can be fused with a diphosphate synthase or isopentenyl transferase gene. It will generally be understood by those skilled in the art that fusions can come from structural rearrangements, such as translocations and deletions, transcriptional read-through of adjacent genes, or trans- and cis-splicing of mRNA precursors. It will generally be understood that the examples provided above are not exhaustive, and gene fusion methods are acceptable.

[0088] In some instances, the host cell may also include a polynucleotide sequence encoding a geranyl synthase (GES) separated from a plant. The polynucleotide sequence encoding the geranyl synthase (GES) separated from a plant may be located on a first or second vector. In one example, the polynucleotide sequence encoding the geranyl synthase (GES) separated from a plant is located on a first vector. In a preferred example, the polynucleotide sequence encoding the geranyl synthase (GES) separated from a plant is located on a second vector.

[0089] The plant may be, but is not limited to, basil (Ocimum basilicum), valerian (Valeriana officinalis), sweet tongue grass (Phyla dulcis), fine hair camphor (Cinnamomum tenuipile) and camptotheca acuminate.

[0090] In one example, the GES is isolated from Ocimum basilicum and comprises the polynucleotide sequence shown in SEQ ID NO:16.

[0091] The polynucleotide sequence encoding GES may be located upstream or downstream of a polynucleotide sequence encoding a diphosphate synthase or isopentenyl transferase. The polynucleotide sequence encoding GES may be located upstream or downstream of a polynucleotide sequence encoding a Nudix pathway gene.

[0092] GES can be co-expressed with diphosphate synthase or isopentenyl transferase gene or Nudix pathway gene. GES can also be co-expressed with diphosphate synthase gene and Nudix pathway gene. In one example, GES can be fused with diphosphate synthase or isopentenyl transferase gene. It will be appreciated by those skilled in the art that fusion can come from structural rearrangement, such as translocation and deletion, transcriptional read-through of adjacent genes or trans and cis splicing of mRNA precursors. It will be appreciated that the examples provided above are not exhaustive, and gene fusion methods are acceptable.

[0093] In some examples, the host cell may also include a polynucleotide sequence encoding multiple antibiotic resistance proteins (MarA). The polynucleotide sequence encoding MarA may be located on the first vector or the second vector, or incorporated into the genome of the host cell. In one example, the polynucleotide sequence encoding MarA is located on the first vector. In a preferred example, the polynucleotide sequence encoding MarA is located on the second vector.

[0094] The polynucleotide sequence encoding MarA may be located upstream or downstream of a polynucleotide sequence encoding a diphosphate synthase or an isopentenyl transferase.The polynucleotide sequence encoding MarA may be located upstream or downstream of a polynucleotide sequence encoding a Nudix pathway gene.

[0095] In some examples, the host cell may further comprise a polynucleotide sequence encoding an alcohol acyltransferase (AAT). The polynucleotide sequence encoding an alcohol acyltransferase (AAT) may be located on the first or second vector. In one example, the polynucleotide sequence encoding an alcohol acyltransferase (AAT) is located on the second vector.

[0096] The polynucleotide sequence encoding AAT may be located upstream or downstream of a polynucleotide sequence encoding a diphosphate synthase or isopentenyl transferase. The polynucleotide sequence encoding AAT may be located upstream or downstream of a polynucleotide sequence encoding a Nudix pathway gene.

[0097] In one example, the AAT enzyme is isolated from a plant. The plant may be, but is not limited to, a modern rose.

[0098] The host cell of the present invention may lack one or more genes. In some examples, the host cell may lack the pta gene, the ackA gene, or the pta and ackA genes.

[0099] In other examples, the host cell may lack at least one gene involved in amino acid synthesis, terpenoid oxidation, and amino acid degradation. Those skilled in the art will recognize that in the case where the host cell lacks at least one gene, these genes may be a combination of genes involved in different processes. For example, the host cell may lack one or more genes involved in amino acid synthesis, and one or more genes involved in terpenoid oxidation. In another example, the host cell may lack one or more genes involved in amino acid synthesis, and one or more genes involved in amino acid degradation. In another example, the host cell may lack one or more genes involved in terpenoid oxidation, and one or more genes involved in amino acid degradation. It should generally be understood that the examples provided above are not exhaustive, and different combinations are acceptable.

[0100] The genes involved in the oxidation of terpenoids may be, but are not limited to, yjgB, yahK, and yddN. Those skilled in the art will recognize that the host cell may lack a combination of genes involved in the oxidation of terpenoids.

[0101] The genes involved in amino acid synthesis may be, but are not limited to, aroA, aroB and serC. Those skilled in the art will recognize that the host cell may lack a combination of genes involved in amino acid synthesis.

[0102] The gene involved in amino acid degradation may be, but is not limited to, tnaA.

[0103] It is generally understood that the host cell may lack one or more of the following genes: ack gene, pta gene, amino acid synthesis, terpenoid oxidation and / or amino acid degradation genes in various combinations. In one example, the host cell lacks aroA, serC, yjgB, tnaA and ack. In another example, the host cell lacks aroA, serC, tnaA and pta genes. In a preferred example, the host cell lacks aroA, serC, yjgB and tnaA genes. In another preferred example, the host cell lacks aroA, serC and tnaA genes.

[0104] The host cell can be modified by a genome modification method to lack ack genes, pta genes, amino acid synthesis genes, terpenoid oxidation genes, and amino acid degradation genes. The reduction of gene expression levels can be performed using genome modification methods, including but not limited to siRNA knockdown and shRNA knockdown. The gene can be deleted from the host cell genome using genome modification methods, including but not limited to CRISPR-Cas9, FRT gene deletion, and TALEN-mediated gene knockout.

[0105] As described herein, the host cell of the present invention can be a bacterial cell. The bacterial cell can be, but is not limited to, Escherichia, Pantoea, Bacillus, Corynebacterium, Paracoccus, Streptomyces, and Synechococcus. In a preferred embodiment, the bacterial cell is an Escherichia coli cell. It is generally understood that any industrial bacteria or bacterial cell can be used in the present invention.

[0106] The strain of Escherichia coli cell can be but not limited to BL21 DE3 strain, K-12 (RV308), K-12 (HMS174), K-12 substr.MG1655, W strain (ATCC9637), JM109 (DE3), BW25113, JM109 DE3, Mach1 and any strain comprising T7 RNA polymer gene. In a preferred embodiment, the Escherichia coli cell is BL21 DE3 strain.

[0107] In another aspect, the present invention relates to an engineered fusion protein produced comprising a diphosphate synthase or prenyltransferase and a Nudix hydrolase of the mevalonate pathway described herein; a diphosphate synthase or prenyltransferase, a Nudix hydrolase, and a geranyl synthase (GES) of a terpene synthase pathway described herein; or a diphosphate synthase or prenyltransferase of the mevalonate pathway described herein and a GES of a terpene synthase pathway.

[0108] The polynucleotide sequence encoding the terpene synthase pathway GES may be located upstream or downstream of the polynucleotide sequence encoding the diphosphate synthase or isopentenyl transferase. The polynucleotide sequence encoding the terpene synthase pathway GES may be located upstream or downstream of the polynucleotide sequence encoding the Nudix pathway gene.

[0109] In one example, the GES of the terpene synthase pathway is located between the genes of the diphosphate synthase or prenyltransferase and the Nudix pathway.

[0110] The GES of the terpene synthase pathway can be fused to a diphosphate synthase gene, an isopentenyl transferase gene, or a gene of the Nudix pathway. The GES of the terpene synthase pathway can be fused to a diphosphate synthase gene or an isopentenyl transferase gene, or to a gene of the Nudix pathway. It will generally be understood by those skilled in the art that fusions can come from structural rearrangements, such as translocations and deletions, transcriptional read-through of adjacent genes, or trans- and cis-splicing of mRNA precursors. It will generally be understood that the examples provided above are not exhaustive, and gene fusion methods are acceptable.

[0111] The diphosphate synthase or isopentenyl transferase of the engineered fusion protein can be located upstream or downstream of the Nudix hydrolase. It will be generally understood by those skilled in the art that each strand of a DNA or RNA has a 5' end and a 3' end, which are named according to the carbon position on the deoxyribose (or ribose) ring. It will also be understood by those skilled in the art that the terms "upstream" and "downstream" refer to the orientation reflecting the synthesis of mRNA and its translation direction from the 5' end to the 3' end. The term "upstream" refers to the 5' end of the coding strand of the gene in question, and the region of the coding strand close to the 3' end is called downstream.

[0112] The engineered fusion protein may also comprise one or more linker sequences.

[0113] In some examples, the linker sequence of the engineered fusion protein can be located between the Nudix hydrolase and the diphosphate synthase or isopentenyl transferase of the fusion protein, wherein the linker is connected to the C-terminus of the Nudix hydrolase and the N-terminus of the diphosphate synthase or isopentenyl transferase. In another example, the linker is connected to the N-terminus of the Nudix hydrolase and the C-terminus of the diphosphate synthase or isopentenyl transferase.

[0114] In some examples, the linker sequence of the engineered fusion protein can have at least 70%, 75%, 80%, 85%, 90%, 95%, and 100% sequence identity to SEQ ID NO:17 or SEQ ID NO:18.

[0115] In another aspect, the present invention relates to a method for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, comprising culturing a host cell as described herein in a culture medium. The host cell can be cultured in a suitable culture vessel, including but not limited to a test tube, a flask, or a bioreactor.

[0116] The method for producing geraniol, geranyl acetate, or geraniol and geranyl acetate may further include the step of separating geraniol, geranyl acetate, or geraniol and geranyl acetate from the culture medium.

[0117] The method includes cultivating the host cell described herein in a culture medium. The culture medium may include, but is not limited to, components in TB culture medium and 2XPY culture medium. Additional components may be added to the culture medium and include antibiotics, inducing agents, and carbon substrates.

[0118] Antibiotics can be added to the culture medium at the beginning of the culture process. Antibiotics can be added continuously throughout the culture process. Antibiotics include kanamycin and spectinomycin.

[0119] The culture medium can also be supplemented with one or more inducing agents that can induce an inducible promoter. The inducing agent can be added to the culture medium at the beginning of the culture process. When the host cells grow to optical density, the inducing agent can be supplemented in the culture medium. During the whole culture process, the culture medium can be continuously supplemented. In another example, the host cells can be cultured under the conditions suitable for inducing an inducible promoter.

[0120] Examples of the inducer include, but are not limited to, galactose, lactose, or isopropyl β-D-1 thiogalactoside (IPTG). In a preferred embodiment, the inducer is lactose or IPTG.

[0121] The concentration of IPTG can be about 0.01mM to about 0.15mM, for example, the concentration of IPTG can be about 0.01mM, about 0.02mM, about 0.03mM, about 0.04mM, about 0.05mM, about 0.06mM, about 0.07mM, about 0.08mM, about 0.09mM, about 0.10mM, about 0.11mM, about 0.12mM, about 0.13mM, about 0.14mM and about 0.15mM. In a preferred embodiment, the concentration of IPTG is about 0.05mM.

[0122] Substratum can also comprise at least one carbon matrix, and carbon matrix can be but not limited to glucose, glycerine, lactose and sucrose.It should be understood by those skilled in the art that substratum can contain the carbon matrix of single type or the combination of carbon matrix.In preferred example, substratum comprises lactose, glucose and glycerine.

[0123] The concentration of lactose can be about 5mM to about 50mM. For example, the concentration of lactose can be about 5mM, about 10mM, about 15mM, about 20mM, about 25mM, about 30mM, about 35mM, about 40mM, about 45mM and about 50mM. In a preferred embodiment, the concentration of lactose is about 40mM.

[0124] The concentration of glucose can be about 2 g / L to about 3 g / L. For example, the concentration of glucose can be about 2.0 g / L, about 2.1 g / L, about 2.2 g / L, about 2.3 g / L, about 2.4 g / L, about 2.5 g / L, about 2.6 g / L, about 2.7 g / L, about 2.8 g / L, about 2.9 g / L, and about 3.0 g / L.

[0125] The concentration of glycerol can be from about 8 g / L to about 30 g / L. For example, the concentration of glycerol can be from about 8 g / L, about 9 g / L, about 10 g / L, about 11 g / L, about 12 g / L, about 13 g / L, about 14 g / L, about 15 g / L, about 16 g / L, about 17 g / L, about 18 g / L, about 19 g / L, about 20 g / L, about 21 g / L, about 22 g / L, about 23 g / L, about 24 g / L, about 25 g / L, about 26 g / L, about 27 g / L, about 28 g / L, about 29 g / L, and about 30 g / L.

[0126] In some examples, the culture medium may include a nitrogen supplement. The nitrogen supplement may be, but is not limited to, tryptone, nitrate, ammonium, urea, and proteose-peptone.

[0127] In a preferred embodiment, the nitrogen supplement is tryptone. The concentration of tryptone can be about 1 g / L to about 10 g / L. For example, the concentration of tryptone can be about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L and about 10 g / L.

[0128] In some examples, the culture medium may include an organic solvent. The organic solvent may be, but is not limited to, dodecane, vegetable oil, undecane, isoamyl laurate, and isopropyl myristate.

[0129] The ratio of dodecane to the culture medium can be about 0.2 to about 1.0. For example, the ratio of dodecane to the culture medium can be about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9 and about 1.0.

[0130] The culture medium can be maintained at a pH of about 6.5 to about 7.5. For example, the pH can be about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, and about 7.5. In a preferred embodiment, the pH is about 7.0.

[0131] In some examples, the method of producing geraniol, geranyl acetate, or geraniol and geranyl acetate comprises culturing the host cell in a culture medium for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days. In a preferred embodiment, the host cell is cultured in a culture medium for about 3 days or about 4 days.

[0132] In one example, after 3 days of cultivation, the yield of geraniol produced in a test tube can be about 292 mg / L to about 684 mg / L. For example, the yield of geraniol produced in a test tube can be about 300 mg / L, about 325 mg / L, about 350 mg / L, about 375 mg / L, about 400 mg / L, about 425 mg / L, about 450 mg / L, about 475 mg / L, about 500 mg / L, about 525 mg / L, about 550 mg / L, about 575 mg / L, about 600 mg / L, about 625 mg / L, about 650 mg / L, about 675 mg / L and about 700 mg / L.

[0133] In one example, after 3 days of cultivation, the yield of geraniol produced in the flask can be as high as about 907 mg / L. For example, the yield of geraniol produced in the flask can be about 50 mg / L, about 100 mg / L, about 150 mg / L, about 200 mg / L, about 250 mg / L, about 300 mg / L, about 350 mg / L, about 400 mg / L, about 450 mg / L, about 500 mg / L, about 550 mg / L, about 600 mg / L, about 650 mg / L, about 700 mg / L, about 750 mg / L, about 800 mg / L, about 850 mg / L and about 900 mg / L.

[0134] In one example, the carbon yield can be at least 24%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, and wherein the carbon yield is calculated as the ratio of the product obtained to the total metabolizable carbon source used.

[0135] The host cells may be cultured in a batch fermentation medium or a fed-batch fermentation medium.

[0136] Batch fermentation medium or fed-batch fermentation medium can include but is not limited to the components in TB medium and 2XPY medium. The components that can be added to the medium include one or more antibiotics, one or more inducing agents, one or more carbon substrates and / or one or more organic solvents.

[0137] Antibiotics can be added to the culture medium at the beginning of the culture process. Antibiotics can be added continuously throughout the culture process. Antibiotics include kanamycin and spectinomycin.

[0138] The inducer in the culture medium capable of inducing the inducible promoter may be, but is not limited to, galactose, lactose or isopropyl β-D-1 thiogalactoside (IPTG). In a preferred embodiment, the inducer is lactose or IPTG.

[0139] The at least one carbon substrate may be, but is not limited to, glucose, glycerol, lactose, and sucrose. In some examples, it will be appreciated by those skilled in the art that the culture medium may contain a combination of carbon substrates.

[0140] The organic solvent in the culture medium may be, but is not limited to, dodecane, vegetable oil, undecane, isoamyl laurate, and isopropyl myristate.

[0141] In some examples, the culture medium may include a nitrogen supplement. The nitrogen supplement may be, but is not limited to, tryptone, nitrate, ammonium, urea, and peptone.

[0142] In one example, the batch fermentation medium can include glucose, glycerol, lactose, and IPTG.

[0143] The concentration of glucose in the batch fermentation medium can be about 1 g / L to about 10 g / L. For example, the concentration of glucose can be about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L, and about 10 g / L. In a preferred embodiment, the concentration of glucose in the batch fermentation medium is about 1 g / L to about 2 g / L.

[0144] The concentration of glycerol in the batch fermentation medium can be about 1 g / L to about 30 g / L. For example, the concentration of glycerol can be about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L, about 10 g / L, about 11 g / L, about 12 g / L, about 13 g / L, about 14 g / L, about 15 g / L, about 16 g / L, about 17 g / L, about 18 g / L, about 19 g / L, about 20 g / L, about 21 g / L, about 22 g / L, about 23 g / L, about 24 g / L, about 25 g / L, about 26 g / L, about 27 g / L, about 28 g / L, about 29 g / L, and about 30 g / L. In a preferred embodiment, the concentration of glycerol in the batch fermentation medium is about 8 g / L to about 10 g / L.

[0145] The concentration of lactose in the batch fermentation medium can be about 5mM to about 50mM. For example, the concentration of lactose can be about 5mM, about 10mM, about 15mM, about 20mM, about 25mM, about 30mM, about 35mM, about 40mM, about 45mM and about 50mM. In a preferred embodiment, the concentration of lactose is about 40mM.

[0146] The concentration of IPTG in batch fermentation medium can be about 0.01mM to about 0.2mM. For example, the concentration of IPTG can be about 0.01mM, about 0.02mM, about 0.03mM, about 0.04mM, about 0.05mM, about 0.06mM, about 0.07mM, about 0.08mM, about 0.09mM, about 0.10mM, about 0.11mM, about 0.12mM, about 0.13mM, about 0.14mM, about 0.15mM, about 0.16mM, about 0.17mM, about 0.18mM, about 0.19mM and about 0.20mM. In a preferred embodiment, the concentration of IPTG is about 0.10mM.

[0147] When the host cells grow to an optical density (OD 600) is about 0.5 to about 2, the carbon substrate and IPTG can be supplemented in the batch fermentation medium. The optical density can be about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9 and about 2.0. In a preferred embodiment, OD 600 It is about 1.0.

[0148] In one example, the fed-batch fermentation medium can include IPTG, magnesium sulfate, and glucose or glycerol.

[0149] The concentration of IPTG in the fed-batch fermentation medium can be about 0.01mM to about 0.2mM. For example, the concentration of IPTG can be about 0.01mM, about 0.02mM, about 0.03mM, about 0.04mM, about 0.05mM, about 0.06mM, about 0.07mM, about 0.08mM, about 0.09mM, about 0.10mM, about 0.11mM, about 0.12mM, about 0.13mM, about 0.14mM, about 0.15mM, about 0.16mM, about 0.17mM, about 0.18mM, about 0.19mM and about 0.20mM. In a preferred embodiment, the concentration of IPTG is about 0.1mM.

[0150] In the fed-batch fermentation medium, the concentration of glucose or glycerol can be about 200 g / L to about 750 g / L. For example, the concentration of glucose or glycerol can be about 200 g / L, about 225 g / L, about 250 g / L, about 275 g / L, about 300 g / L, about 325 g / L, about 350 g / L, about 375 g / L, about 400 g / L, about 425 g / L, about 450 g / L, about 475 g / L, about 500 g / L, about 525 g / L, about 550 g / L, about 575 g / L, about 600 g / L, about 625 g / L, about 650 g / L, about 675 g / L, about 700 g / L, about 725 g / L, and about 750 g / L. In a preferred example, the concentration of glucose or glycerol in the fed-batch fermentation medium may be about 500 g / L.

[0151] The concentration of magnesium sulfate in the fed-batch fermentation medium can be about 1 g / L to about 10 g / L. For example, the concentration of magnesium sulfate can be about 1 g / L, about 2 g / L, about 3 g / L, about 4 g / L, about 5 g / L, about 6 g / L, about 7 g / L, about 8 g / L, about 9 g / L, and about 10 g / L. In a preferred example, the concentration of magnesium sulfate in the fed-batch fermentation medium can be about 5 g / L.

[0152] Throughout the process, the carbon substrate and magnesium sulfate can be continuously supplemented in the fed-batch fermentation medium at a feed rate of about 0.6 g / L / h / reactor volume to about 6 g / L / h / reactor volume. For example, the feed rate can be about 0.6 g / L / h / reactor volume, about 1.0 g / L / h / reactor volume, about 1.5 g / L / h / reactor volume, about 2.0 g / L / h / reactor volume, about 2.5 g / L / h / reactor volume, about 3.0 g / L / h / reactor volume, about 3.5 g / L / h / reactor volume, about 4.0 g / L / h / reactor volume, about 4.5 g / L / h / reactor volume, about 5.0 g / L / h / reactor volume, about 5.5 g / L / h / reactor volume, and about 6.0 g / L / h / reactor volume.

[0153] When the host cells grow to an optical density (OD 600 ) is about 10 to about 60, IPTG can also be supplemented in the fed-batch fermentation medium. The optical density can be about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55 and about 60. In a preferred embodiment, the OD 600 From about 30 to about 50.

[0154] The batch fermentation medium or the fed-batch fermentation medium can be maintained at a pH of about 6.5 to about 7.5. For example, the pH can be about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, and about 7.5. In a preferred embodiment, the pH is about 7.0.

[0155] In one example, the yield of geraniol produced in fed-batch fermentation can be at least 1 g / L. For example, the yield of geraniol produced in fed-batch fermentation can be at least 1 g / L, at least 5 g / L, at least 10 g / L, at least 15 g / L, at least 20 g / L, at least 25 g / L, at least 30 g / L, at least 35 g / L, at least 40 g / L, at least 45 g / L and at least 50 g / L.

[0156] In one example, the yield of geranyl acetate produced in fed-batch fermentation can be about 4 g / L to about 40 g / L. For example, the yield of geranyl acetate produced in fed-batch fermentation is about 4 g / L, about 5 g / L, about 10 g / L, about 15 g / L, about 20 g / L, about 25 g / L, about 30 g / L, about 35 g / L and about 40 g / L.

[0157] In another aspect, the invention relates to a kit for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, wherein the kit comprises a host cell as described herein and instructions for use.

[0158] In some examples, the host cells in the kit can be dissolved in solution or lyophilized.

[0159] In some examples, host cells can be preserved by deep freezing.

[0160] The invention illustratively described herein may be suitably practiced in the absence of any element or elements, any limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", and the like should be interpreted broadly and without limitation. Furthermore, the terms and expressions used herein have been used as descriptive terms, rather than limiting terms, and when using these terms and expressions, it is not intended to exclude any equivalents of the features shown and described, or portions thereof, but it should be recognized that various modifications are possible within the scope of the claimed invention. Therefore, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, those skilled in the art may resort to modifications and variations of the invention embodied therein disclosed herein, and such modifications and variations are considered to be within the scope of the present invention.

[0161] The present invention has been described extensively and generically herein. Each narrower category and subgeneric grouping that falls within the generic disclosure also forms a part of the present invention. This includes generic description of the present invention in the context of a proviso or negative limitation that deletes any subject matter from the generic concept, regardless of whether the deleted material is specifically described herein.

[0162] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0163] Experimental Section

[0164] Non-limiting examples and comparative examples of the present invention will be further described in more detail with reference to specific examples, which should not be construed as limiting the scope of the present invention in any way.

[0165] Materials and methods

[0166] Strain and plasmid construction

[0167] Monoterpenoids were produced using Escherichia coli BL21 DE3 strain. Plasmids were constructed by combining the operons hmgS-atoB-hmgR and mevK-pmk-pmd-idi into a p15A-spec(L2-8) vector with three different promoters (TM1, TM2 and TM3). The new plasmid set included 9 plasmids, namely spk001-spk009 (Table 1). Plasmids carrying RhNUDX1 and various GPPS (AgGPPS, ispA_S80F and ERG20 mutants) were cloned into the p15A-kan vector (as spk001-002d, Table 1). The best geraniol strain carried two plasmids, sps004 and spk002 (RhNUDX1 and AgGPPS). For the geranyl acetate plasmid, the gene RhAAT1 was inserted into spk002 after AgGPPS, and the resulting plasmid was named spk003. As previously described, the genes tnaA, YjgB, and ackA-pta were deleted using the CRISPR-Cas9 method using the gRNAs listed in Table 2. The plasmids, oligonucleotides, and strains used in this study are summarized in Tables 1, 2, and 3, respectively.

[0168] Table 1. Plasmid information

[0169]

[0170] 1 sps001-009 expresses two modules, M1 and M2.

[0171] 2 The relative strengths of TM1, TM2 and TM3 promoters relative to T7 promoter were 92%, 37% and 16%, respectively.

[0172] 3 GPPS used in this study. GPPS1-ispA_S80F is from Escherichia coli; GPPS2-truncated AgGPPS is from Abies grandis; GPPS3-Erg20_N127W is from Saccharomyces cerevisiae; GPPS3a-Erg20_F96W; GPPS3c-Erg20_F96W_N127W. RBS information is shown in Table 2.

[0173] 4 Module M1 contains three genes - HmgS, thmgR and atoB.

[0174] 5 Module M2 contains three genes - mevK, pmk, pmd and idi.

[0175] 6 Module M3 has a different design, details are given in the notes.

[0176] Table 2. Oligonucleotide sequences used in this study

[0177]

[0178] Table 3. Strain information

[0179]

[0180]

[0181]

[0182] Under the CRISPR-Cas9 method, different pTarget plasmids with various sgRNAs were obtained by restriction free (RF) cloning method. Asymmetric homology arm (HA) donor DNA was amplified from the Escherichia coli genome using iProof PCR mix (BioRad) and column purified with Zymoclean Gel DNA Recovery Kit (ZymoResearch). Typically, 100-200ng / μl donor DNA can be obtained in 30μl in a 100μl PCR reaction. For primer design, the forward primer is a fusion of the upstream homology arm (40-45bp) sequence and the downstream homology arm (15-20bp) sequence. The 15-20bp downstream homology arm is used for annealing in the initial cycle of PCR, and its length is selected according to Tm of about 50°C. The total length of the forward primer is maintained at 60bp. The reverse primer is a normal PCR primer of about 15-20bp, with a Tm of about 50°C. The length of the downstream homology arm can vary depending on the reverse primer selected. The length of the downstream homology arm was maintained at 500 bp. BL21 chemically competent cells were prepared using the Mix&Go! E.coli Transformation Kit (Zymo Research). To construct BL21 cells containing the pCas plasmid, 10 μl of cells were mixed with 50 ng / μl pCas plasmid and heat shocked at 42°C for 45 s. Te cells were rescued for 1 h in 200 μl LB medium, 30°C, 300 rpm, and then plated on LB agar containing kanamycin (50 μg / ml) and incubated overnight at 30°C. Pick a single colony, inoculate it in 1 ml of LB medium containing kanamycin (50 μg / ml), and incubate it overnight at 30°C, 300 rpm to prepare electrocompetent cells. To prepare electrocompetent cells, the OD containing the pCas plasmid was 600An overnight BL21 cell culture at OD 0.1 was inoculated into 10 ml of LB medium containing kanamycin (50 μg / ml) and cultured at 30°C and 300 rpm. 600 At OD 0.2, 20 mM arabinose was added to the culture to induce λ-Red recombinase. 600 The bacterial cells were harvested at 0.6 and centrifuged at 3800 rpm for 10 min at 4 ° C. The supernatant was discarded and the cells were resuspended in 10 ml of 10% glycerol. The washing step was repeated twice. The electrocompetent cells were then suspended in 100 μl of 10% glycerol. For electroporation, 20 μl of cells were mixed with 100 ng / μl pTarget plasmid and 100 ng donor DNA in a 1 mm Gene Pulser cuvette (Bio-Rad) and electroporated at 1.8 kV. In 500 μl LB culture medium, at 30 ° C and 300 rpm, the cells were rescued for 3 h, then plated on LB agar containing kanamycin (50 μg / ml) and spectinomycin (100 μg / ml), and incubated overnight at 30 ° C. Colonies were screened by colony PCR using 2×PCRBIO Ultra Mix (PCRBiosystems) and an unedited BL21 strain as a control. The plasmids, oligonucleotides, and strains used in this study are summarized in Tables 1 , 2 , and 3 , respectively.

[0183] Enzyme fusion

[0184] RhNUDX1 was fused to ispA_S80F in the orientation of RhNUDX1-ispA_S80F. Two linkers (short, GGGGSGGPGS (SEQ ID NO: 17); and medium, GGGGSGGGGSGGGGSGGPGS (SEQ ID NO: 18) (Table 4) were used. The two fusion proteins were obtained using an in-house cloning method modified from the Agilent QuikChange II method using the primers in Table 2 (spk2m1-f / r and spk2s1-f / r). Specifically, iProofTM High-Fidelity DNA Polymerase (iProof TMHigh-fidelity DNA polymerase) amplified a PCR fragment with a complementary extension of 14bps to the end of the vector. Perform a gel check to ensure that the amplified product is the correct size. The amplified DNA fragment was treated with DpnI for 3h. The PCR product was then purified using the Omega PCR Cycle Pure Kit. It was then treated with Takara seamless cloning mixture (Takara infusion cloning mix) at 50°C for 15min. 1μL of the treated product was transformed into 20μL DH5α competent cells, rescued for 1h, and then plated on LB plates supplemented with 50μg / mL kanamycin.

[0185] Table 4. RBS sequences of various GPPS used in this study

[0186]

[0187] Culture medium and culture conditions

[0188] Chemically defined medium (or defined medium) contained 10 g / L glucose, 2 g / L (NH4)2SO4, 4.2 g / L KH2PO4, 11.24 g / L K2HPO4, 1.7 g / L citric acid, 0.5 g / LMgSO4, and 10 ml / l trace element solution, pH 7.0. Trace element solution (100X) contained 0.25 g / L CoCl2·6H2O, 1.5 g / L MnSO4·4H2O, 0.15 g / L CuSO4·2H2O, 0.3 g / L H3BO3, 0.25 g / L Na2MoO4·2H2O, 0.8 g / L Zn(CH3COO)2, 5 g / L Fe(III) citric acid, and 0.84 g / L EDTA, pH 8.0.

[0189] Semichemically defined medium was identical to defined medium except supplemented with 2 g / L tryptone for geraniol production in flasks.

[0190] Auto-induction defined medium (AIDM): 2-3 g / L glucose, 8-30 g / L glycerol and 5-50 mM lactose (as inducer). The remaining ingredients are the same as defined medium. Geranyl acetate is produced using Terrific Broth (TB, 12 g / L tryptone, 24 g / L yeast extract, 2.31 g / L KH2PO4, 12.54 g / L K2HPO4) containing 2-3 g / L glucose and 20-30 g / L glycerol. For the automatic induction of geranyl acetate, 5-50 mM lactose is used as an inducer.

[0191] For strain and abiotic optimization, cells were cultured in 14 ml BD Falcon TM 1 ml of defined medium or AID medium in a test tube was grown at 28°C / 300 rpm for 3 days. In addition, monoterpenes were extracted with 200 μL of dodecane during the cell culture. When using defined medium, cells were initially grown at 37°C / 300 rpm until OD 600 Reach 1-2, with 0.01-0.15mM IPTG induction, then grow 2 days at 28 ℃ / 300rpm.For AID medium, cells are grown 3 days at 28 ℃ / 300rpm and are automatically induced by lactose.All cultures are supplemented with antibiotics (50μg / ml kanamycin and 100μg / ml spectinomycin) to maintain two plasmids.

[0192] Flask conditions (100 rpm, 200 rpm and 300 rpm)

[0193] For the production of geraniol, cells were inoculated in 10 mL AIDM or semi-chemically defined medium in a 125 mL baffled flask for 3 days at 28°C, 100-300 rpm. 10-100% dodecane / sunflower oil was used as the product extractant. On the other hand, for geranyl acetate, TB autoinduction medium was used and the medium was supplemented with 20% dodecane / sunflower oil. The rest of the settings were the same as for geraniol.

[0194] All cultures were supplemented with antibiotics (50 μg / ml kanamycin and 100 μg / ml spectinomycin) to maintain both plasmids.

[0195] Bioreactor fermentation

[0196] This study used a 500ml Mini Bioreactor and a 7L Bioreactor (Applikon Biotechnology) with working volumes of 200-400ml and 2-5L, respectively. The cells (-80°C stock solution) were grown in 10ml of defined medium at 37°C for 48h. Two modes were tested. The first mode was an auto-induction batch fermentation, in which no additional nutrients were provided, and the initial medium contained 10g / L glucose, 14-20g / L lactose, 50g / L glycerol, 4-6g / L ammonium sulfate and 1.5g / LMgSO4, and the remaining components remained the same as the defined medium. The second mode was a fed-batch fermentation, in which the process was similar to the previous description. In short, once the OD reached approximately 5-6, it was fed for 0.6h -1The growth rate of the cells was calculated by exponentially adding feed solution (500 g / L glucose and 5 g / L MgSO4) to the bioreactor. When the OD reached about 30-50 (16-18 h after inoculation), the cells were induced with 0.1 mM IPTG. After induction, a constant feed rate of 7.5 g / L / h of glucose and 0.075 g / L / h of MgSO4 was maintained. The culture temperature was adjusted to 30°C, and 15-20% (v / v) of dodecane was supplemented in the bioreactor. During the fermentation process, the dissolved oxygen level was maintained at 30% (800-2000 r.pm) by supplying filtered air at a gas rate of 1.5 vvm. The culture pH was controlled at 7.0 with 28% ammonia solution. Fed-batch experiments were performed in a defined medium without any antibiotics.

[0197] Theoretical yields of geraniol and geranyl acetate

[0198] The production of isoprene pyrophosphate or isopentenyl pyrophosphate (IPP) via the mevalonate pathway under aerobic fermentation conditions requires 3 acetyl-CoA (AcCoA), 3 ATP, and 2 NAD(P)H.

[0199] (1) 1.5 glucose (or 3 glycerol) + 2O2 → 3AcCoA + 3ATP + 3CO2 + 6NAD(P)H (glycolysis)

[0200] (2) 3AcCoA+2NAD(P)H→MVA

[0201] (3) MVA+3ATP→IPP+CO2

[0202] (4) 2IPP→Geraniol

[0203] (5) Glycerol + AcCoA → Geranyl acetate

[0204] In summary, 3 glucose (or 6 glycerol) + 4O2 → geraniol + 8CO2 + 10H2O, and 7 / 2 glucose (or 7 glycerol) + 14 / 3O2 → geranyl acetate + 9CO2 + 10H2O, therefore, the mass yields of geraniol and geranyl acetate are 28.6% and 31.1% for glucose or glycerol, respectively.

[0205] Quantification of terpenoids

[0206] Terpenoid samples were prepared by diluting 0.5-20 μl of the organic layer into 1000 μl of hexane. Samples were analyzed on an Agilent 7890 gas chromatograph equipped with an Agilent 5977B MSD. At 240 ° C, the sample was injected into an Agilent VF-WAXms column with a split ratio of 40: 1. The oven program started at 100 ° C for 1 minute, increased to 150 ° C at 50 ° C / min, then increased to 240 ° C at 15 ° C / min, and maintained at 240 ° C for another 2 min. The concentration of the compound was calculated by interpolation of the standard curve prepared by a reliable terpene standard (MilliporeSigma, Singapore). Since the citral standard has two peaks (α-citral and β-citral), their concentrations are estimated based on the relative ratio of their chromatographic peak areas. The mass spectrometer was operated in EI mode to perform full scan analysis (m / z 30-300, 2 spectra / s).

[0207] result

[0208] In vitro characterization of RhNUDX1

[0209] Before using RhNUDX1 to produce geraniol in vivo, RhNUDX1 was first expressed in E. coli BL21 strain and the enzyme was purified. Based on characterization, the purified RhNUDX1 (purity of about 65.3%, Figure 2 A) in k cat and K m The values ​​were 0.36±0.07s -1 and 46.4±4.4μM. Here, k cat and K m The values ​​are higher than those reported previously (Table 5), which may be because the previous study used a NusA-RhNUDX1 fusion protein, while the present study used wild-type RhNUDX1 for enzyme characterization. cat / K m The values ​​were comparable to or even better than those of GES from Ocimum basilicum (sweet basil) (Table 5). The optimal pH value was that RhNUDX1 had the highest in vitro activity at pH 8, and it completely lost its activity when the pH dropped below 6 ( Figure 2 B).

[0210] Table 5. Enzyme information

[0211]

[0212]

[0213] 1 NN terminal truncation from the 2nd to the 85th amino acid

[0214] 2 Use single and double mutants: N127W, N127W-F96W

[0215] Production of geraniol in Escherichia coli using RhNUDX1

[0216] Next, RhNUDX1 was expressed in wild-type E. coli. Indeed, it produced a small amount of geraniol (about 1.0 mg / L), and 0.3 mg / L of geranial (or α-citral) and trace amounts of citronellol were also detected as byproducts ( Figure 2 C in Figure ). Then, the mevalonate pathway genes ( Figure 1 ) to provide more terpene precursors (isopentenyl diphosphate, or IPP and dimethylallyl diphosphate, or DMAPP), which increased the yield of geraniol to about 28.2 mg / L. Interestingly, only about 0.04 mg / L of geraniol was detected in E. coli expressing mevalonate pathway genes but not RhNUDX1, which may be the result of native E. coli enzymes (e.g., NudB, AphA). Since GPP is an intermediate of farnesyl diphosphate (FPP, C15) synthase (ispA) in E. coli and is rapidly converted to FPP, a truncated GPPS (AgGPPS) from Abies grandis was further expressed to increase the GPP supply ( Figure 1 By combining GPPS with overexpression of mevalonate pathway enzymes, the production of geraniol increased to 92.0 mg / L, the production of geranyl aldehyde was about 14.8 mg / L, and the production of citronellol was 0.4 mg / L. For all strains, the cell density was similar in the range of 9.6-11.6 ( Figure 2 D), indicating that the cells were not severely inhibited by the amount of geraniol produced.

[0217] Enhances the supply of monoterpene precursor GPP

[0218] Since overexpression of GPPS resulted in an increase in geraniol production to more than 3 times, GPP may still limit the production of geraniol. Therefore, various GPPS were explored: AgGPPS, two FPP synthase (ERG20) mutants from Saccharomyces cerevisiae; and an FPP synthase mutant (IspA_S80F) from Escherichia coli. Based on previous studies, two ERG20 mutants with reduced FPP synthase activity were selected for the production of geraniol: ERG20_N127W and F96W-N127W (or ERG20_96_127). In addition, the ribosome binding sites (RBS) of various GPPS were interfered with (see Table 3 for details). It was found that the combination of IspA_S80F and RBS-4 resulted in the highest yield of geraniol, approximately 128.2 mg / L ( Figure 3The AgGPPS strain produced more geraniol (61-73 mg / L) than the two yeast ERG20 mutants (19-58 mg / L), but at a lower efficiency than IspA_S89F. In addition, for eukaryotic GPPS, RBS-2 resulted in higher geraniol production than RBS-1 or RBS-3; for bacterial GPPS (IspA_S80F), RBS-4 was superior to RBS-5 ( Figure 3 In addition, the biomass of all strains was similar (OD 600 values ​​of 8-10), except for the OD of AgGPPS with RBS-1 600 Slightly higher ( Figure 3 These data suggest that the combination of RBS engineering and selection of appropriate GPPS is an effective strategy.

[0219] Pathway balance and substrate channeling of GPPS fused to RhNUDX1

[0220] After optimizing GPP supply, the mevalonate pathway was further transcriptionally fine-tuned to optimize terpene precursor (IPP and DMAPP) supply ( Figure 1 By dividing the mevalonate pathway into two modules (upper module: including genes atoB, hmgS and truncated hmgR; lower module: including genes mevK, pmK, pmd and idi), the pathway was systematically balanced through promoter engineering, and the optimal strains (strains #32 and #31, Figure 3 C and D in the figure). Strains #32 and #31 produced approximately 181 mg / L and 124 mg / L of geraniol, respectively. After equilibrium in the mevalonate pathway, the substrate channeling strategy was further tested. The rationale is that in E. coli, native ispA may compete with RhNUDX1 for GPP as a substrate. The fusion of GPPS with RhNUDX1 may promote NUDX1 to acquire GPP immediately after GPPS produces GPP. This strategy has been successfully applied to produce C11 terpenoids with significantly increased yields. In the RhNUDX1-GPPS orientation, two linkers were compared: short (GGGGSGGPGS (SEQ ID NO:17)) and medium (GGGGSGGGGSGGGGSGGPGS (SEQ ID NO:18)). The geraniol yield of the short linker (119 mg / L) was approximately twice that of the medium linker (64 mg / L). However, both designs gave lower yields than the non-fused GPPS and NUDX1 ( Figure 4 ). This may be due to the negative impact of the fusion protein on protein folding. Further studies are needed to understand the underlying mechanism.

[0221] Geraniol removal degradation pathway and abiotic optimization

[0222] Next, the goal was to reduce the production of byproducts (geranyl aldehyde and citronellol). In the strains previously constructed, it was observed that different strains had different product distributions. Some strains produced up to 30% (the percentage was calculated by normalizing the total production of the three monoterpenes: geraniol, geranyl aldehyde, and citronellol) of geranyl aldehyde ( Figure 2 C), while some strains produced only 2% geranaldehyde (AgGPPS with RBS-2, Figure 3 Similarly, some strains produced about 8% citronellol, while some strains produced less than 1%. Since geranylaldehyde was the main byproduct, the gene yjgB (alcohol dehydrogenase) was deleted, which is reported to be responsible for the oxidation of geranyl to geranylaldehyde. In fact, the yjbB deletion strain increased the geraniol yield by 47%, from 119 mg / L to 176 mg / L. At the same time, the production of geranylaldehyde decreased by 70%, from 51 mg / L to 15 mg / L ( Figure 5 ).

[0223] Interestingly, during these experiments, it was also observed that the carbon source and inducer had a significant effect on the distribution. Specifically, the percentage of geraniol in the autoinduction defined medium was higher than that in the IPTG-induced defined medium. In view of this serendipitous finding, adjustments to the autoinduction medium and inducer were further explored. Using the two best strains #32 and #31, a series of different concentrations of lactose or IPTG were tested. The geraniol production of strains #32 and #31 gradually increased with increasing lactose concentration and stabilized at 40mM and 30mM lactose, respectively ( Figure 6 A and B in the table). At the same time, the production of geranyl aldehyde and citronellol decreased and was lowest at 30-50 mM lactose (40-50 mM lactose for strain #32; 30-50 mM lactose for strain #31). Under the optimal condition of 40 mM lactose, strain #32 produced 219 mg / L, 10 mg / L, and 2.9 mg / L of geraniol, geranyl aldehyde, and citronellol, respectively (i.e., the percentage of geraniol was close to 97%). In contrast, IPTG dosage adjustment had no significant effect on the production of various monoterpenes in strains #32 and #31 ( Figure 6 In summary, compared with the lactose autoinduction medium, the percentages of geranial (7-18 mg / L, or 15-22%) and citronellol (4.5-9 mg / L, or 5-11%) were relatively higher, while the yield of geraniol (60-80 mg / L, or 65-80%) was relatively lower in the IPTG-induced defined medium.

[0224] Explore other enzymes and combinations

[0225] In addition to the RhNUDX1 enzyme, other types of geraniol-producing enzymes were compared. mThe values ​​were relatively lower than those of other GES from Cinnamomum quinquefolium and Camptotheca acuminata (Campodium album). m value, so ObGES was selected. In addition, NudI of Escherichia coli was also selected, which has more Nudix hydrolases than many other reported microbial Nudix hydrolases. However, it was found that RhNUDX1 outperformed ObGES and NudI in geraniol biosynthesis ( Figure 7 A and B in Figure 1). The geraniol yield using RhNUDX1 was almost twice that of the other two enzymes. We also tested an N-terminally fused ObGES (Cm-Ob) with a chloramphenicol acetyltransferase leader sequence (CM29*), which has been reported to increase geraniol yield. However, in our study, the increase in geraniol yield was very significant ( Figure 7 A and B in ).

[0226] Next, we explored various enzyme combinations with additional GPPS or co-utilization of RhNUDX1 and ObGES. Figure 3 In the experiments, GPP was optimized, but it was speculated that the supply of GPP limited the production of geraniol. If so, the expression of additional GPPS might promote the production of geraniol. However, in all designs (RhNUDX1-ispA, ObGES-ispA, or Cb-Ob), additional AgGPPS reduced the production of geraniol by 7-47% ( Figure 7 A and C in the figure). The combination of RhNUDX1-ObGES-ispA-AgGPPS resulted in the lowest production of geraniol (32.4 mg / L). The data showed that: 1) the oversupply of GPPS was detrimental to geraniol production rather than beneficial; 2) the two enzymes (ObGES and RhNUDX1) seemed to compete with each other rather than act synergistically. The new combination led to perturbations in the entire pathway and reduced geraniol production. Therefore, the mevalonate pathway was reoptimized and a new strain (RhNUDX1-AgGPPS*) was obtained with a higher yield (254 mg / L) than strain 32 (or NUDX1-ispA, Figure 7 C and D in ).

[0227] Biosynthesis of Geranyl Acetate

[0228] With the knowledge gained from geraniol in mind, we explored the potential of using RhNUDX1 and RhAAT1 (rosyl alcohol acyltransferase) to produce geranyl acetate ( Figure 1 ). Using the same pathway balancing strategy, the two strains GA11 and GA21 had the highest geranyl acetate yields ( Figure 8 Further adjustment of the lactose concentration resulted in the highest geranyl acetate production by strain GA11 (686 mg / L, Figure 8B), which is about 1.7 times higher than the yield of geraniol (254 mg / L). Similar promoting effects have been reported before, that is, the esterification of geraniol can increase the product yield.

[0229] Batch and fed-batch fermentation of geraniol and geranyl acetate

[0230] Since auto-induction medium resulted in the highest yield of geraniol by minimizing the degradation of geraniol into other products (geranial and citronellol), a new bioprocess was developed based on the concept of auto-induction medium. High cell density batch fermentation was explored by increasing the supply of key nutrients (carbon, nitrogen and MgSO4). The first medium tested included 10 g / L glucose, 50 g / L glycerol, 20 g / L (58 mM) lactose, 6 g / L (NH4)2SO4 and 1.5 g / L MgSO4. The other nutrients were kept the same as the defined medium we used previously (see Materials and Methods). In this batch fermentation, OD values ​​up to 77 were obtained. 600 , the geraniol titer reached 957 mg / L within 67 h ( Fig. 9 A in ). In addition, it was observed that the production of citronellol increased rapidly in the late fermentation period and reached 250 mg / L at 72 h. At the same time, geraniol and geranal decreased slightly during 67-72 h. In E. coli, citronellol was reduced from geraniol / geranal, however, the enzyme is still unknown. In the future, the identification of this enzyme and its deletion from the genome will be explored to minimize the formation of citronellol.

[0231] Next, the production of geranyl acetate was tested in a fed-batch fermentation, as previously used for the production of viridiflorol and amorphadiene. Within 70 h, strain GA11 produced 2.65 g / L geranyl acetate, with an OD of 1.34. 600 It is 144.

[0232] ackA and pta gene deletion

[0233] When developing this bioprocess, a lot of acetate (up to 10 g / L) was produced together with geranyl acetate. In E. coli, the main pathway for the production of acetate is through acetate kinase (ackA) and phosphate acetyltransferase (pta). Together, these two enzymes convert 1 acetyl-CoA into 1 acetate and 1 ATP. Since the mevalonate and geraniol pathways also start from acetyl-CoA, the production of acetate is in direct competition with the biosynthesis of geraniol. Therefore, the effect of the deletion of ackA and pta on the bioproduction of geranyl acetate was evaluated. The deletion of ackA and pta significantly increased the titer of geranyl acetate by 3.7-4.8 times, from 1.6 g / L to 7.8 g / L in medium with 20 g / L glycerol, or from 2.6 g / L to 9.5 g / L in medium with 30 g / L glycerol ( Fig.10 ). In addition, as evidenced by the pH difference, the production of acetic acid was greatly reduced. After 3 days of cultivation, the pH of the wild type ("-") dropped from 7.2 to about 5.0, indicating a fairly high production of acetic acid. In contrast, the pH of the mutant strain ("ΔackApta") remained constant at about 7.0. The carbon yield reached more than 24% (>24%), which is 2-3 times higher than the best results in the literature.

[0234] In addition to geranyl acetate, deletion of ackA and pta also affected the biosynthesis of geraniol.

[0235] Tryptone supplementation

[0236] Next, the effect of pancreatic peptone supplementation on geraniol production was evaluated. It was observed that pancreatic peptone supplementation had a very positive effect on geraniol production. In the case of only 2g / L pancreatic peptone supplementation, geraniol production increased from 292mg / L to 684mg / L, an increase of 130% ( Fig.11 ). Further increase of tryptone could not improve the yield of geraniol. 600 The change in value is not significant.

[0237] Organic matter impact

[0238] When the strains were tested in flasks, the production of geraniol was always lower than in test tubes, while the production of geranial was higher than in test tubes. It was assumed that extracellular geraniol was unstable and could be oxidized to geranial by oxygen. To test this hypothesis, more organic matter (here dodecane was used) was used in the flasks to prevent further oxidation of geraniol. Therefore, different volume ratios of dodecane to culture medium, 0.1-1, were evaluated. When the ratio was 0.1-0.2, the effect on geraniol was not significant, although the production of geranial increased from 129 mg / L to 276 mg / L. However, when the ratio was further increased to 0.5 and 1.0, the production of geraniol increased significantly and the formation of geranial was also reduced. At a ratio of 1.0, the geraniol titer in the flask increased to 907 mg / L, which was about 2.6 times higher than when the ratio was 0.1-0.2.

[0239] Table 6. Summary of sequence listing

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252] Equivalence

[0253] The above examples are provided to illustrate the purpose of the present invention and should not be construed as imposing any limitation on the scope of the present invention. It is obvious that, without departing from the basic principle of the present invention, many modifications and changes can be made to the specific embodiments of the present invention described above and in the examples. All these modifications and changes are intended to be included by the application.

Claims

1. A host cell comprising one or more vectors comprising polynucleotide sequences encoding one or more genes of a mevalonate pathway and one or more genes of a Nudix pathway.

2. The host cell according to claim 1, wherein the host cell comprises two vectors, wherein a. a first vector comprising a polynucleotide sequence encoding one or more genes of the mevalonate pathway; and b. A second vector comprising a polynucleotide sequence encoding one or more genes of the Nudix pathway.

3. The host cell of claim 1 or 2, wherein the one or more genes of the mevalonate pathway are selected from HMG-CoA synthase (hmgS), acetoacetyl-CoA thiolase (atoB), HMG-CoA reductase (hmgR), mevalonate kinase (mevK), phosphomevalonate kinase (pmk), mevalonate pyrophosphate decarboxylase (pmd) and (isopentenyl diphosphate) IPP isomerase (idi), and the one or more genes of the Nudix pathway are NUDX1 or NudI. The host cell according to claim 3 , wherein the hmgR gene is truncated.

5. The host cell according to any one of claims 2-4, wherein the second vector further comprises a polynucleotide sequence encoding one or more diphosphate synthase genes, isopentenyl transferase genes, or a combination thereof in the host cell.

6. The host cell according to any one of claims 2-5, wherein the polynucleotide sequence in each of the vectors is operably linked to an inducible promoter, wherein the inducible promoter is a wild-type T7 RNA polymerase promoter or a variant of the wild-type T7 RNA polymerase promoter.

7. The host cell according to any one of claims 2 to 6, wherein the first vector comprises: a. a polynucleotide sequence operably linked to a first inducible promoter encoding the hmgS, atoB, and hmgR genes of the mevalonate pathway; and b. A polynucleotide sequence encoding the mevK, pmk, pmd and idi genes of the mevalonate pathway operably linked to a second inducible promoter.

8. The host cell according to any one of claims 5-7, wherein the second vector further comprises a polynucleotide sequence encoding a ribosome binding site (RBS), wherein the polynucleotide sequence is located upstream of the following polynucleotide sequences: the polynucleotide sequence encoding a Nudix pathway gene, the polynucleotide sequence encoding a diphosphate synthase gene or an isopentenyl transferase gene, or a combination thereof.

9. The host cell according to claim 8, wherein the polynucleotide sequence encoding RBS in the second vector is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO:

5.

10. The host cell of any one of claims 5-9, wherein the diphosphate synthase or prenyl transferase is geranyl pyrophosphate synthase (GPPS) or farnesyl diphosphate synthase (FPPS).

11. The host cell of claim 10, wherein the GPPS is isolated from Abies grandis (AgGPPS).

12. The host cell of claim 11, wherein the AgGPPS is truncated at the N-terminus.

13. The host cell according to claim 12, wherein the truncated AgGPPS comprises the polypeptide sequence shown in SEQ ID NO:

7.

14. The host cell according to claim 10, wherein the FPPS is isolated from Saccharomyces cerevisiae or Escherichia coli.

15. The host cell of claim 14, wherein the FPPS is mutated at one or more amino acid positions.

16. The host cell according to claim 15, wherein the mutant FPPS from Escherichia coli comprises the polypeptide sequence shown in SEQ ID NO:9, and wherein the mutant FPPS from Saccharomyces cerevisiae comprises the polypeptide sequence shown in SEQ ID NO:11, SEQ ID NO:12 or SEQ ID NO:

13.

17. The host cell of any one of claims 2-16, wherein the NUDX1 is isolated from a plant.

18. The host cell of claim 17, wherein the NUDX1 is isolated from Rosa hybrida and has about 70%, 80%, 90% or 100% identity with the polypeptide sequence shown in SEQ ID NO: 14, or wherein the NUDX1 is isolated from Arabidopsis thaliana and has about 70%, 80%, 90% or 100% identity with the polypeptide sequence shown in SEQ ID NO:

15.

19. The host cell of any one of claims 2-17, wherein the NudI is isolated from a prokaryotic organism.

20. The host cell of any one of claims 5-19, wherein the NUDX1 or NudI is co-expressed with the diphosphate synthase or isopentenyl transferase.

21. The host cell of any one of claims 5-20, wherein the second vector further comprises one or more of the following: a. a polynucleotide sequence encoding a geranyl synthase (GES) isolated from a plant, wherein the polynucleotide sequence encoding the GES is located upstream of the polynucleotide sequence encoding the diphosphodiesterase or the isopentenyl transferase, and wherein the GES is co-expressed with the diphosphatase or the isopentenyl transferase and / or the Nudix enzyme; b. a polynucleotide sequence encoding a plurality of antibiotic resistance proteins (MarA), the polynucleotide sequence being located downstream of the polynucleotide sequence encoding diphosphate synthase or isopentenyl transferase; or c. A polynucleotide sequence encoding alcohol acyltransferase (AAT), which is located downstream of the polynucleotide sequence encoding diphosphate synthase or isopentenyltransferase or a combination thereof.

22. The host cell of any one of claims 1-21, wherein the host cell lacks the pta gene, the ackA gene, or the ackA and pta genes.

23. The host cell of any one of claims 1-22, wherein the host cell lacks at least one gene involved in amino acid synthesis, terpenoid oxidation, amino acid degradation, or a combination thereof.

24. The host cell of claim 23, wherein the host cell lacks aroA, serC, yjgB and tnaA genes, or wherein the host cell lacks aroA, serC and tnaA genes.

25. The host cell of any one of claims 1-24, wherein the host cell is a bacterial cell.

26. The host cell of claim 25, wherein the bacterial cell is an E. coli cell.

27. Engineered fusion protein, comprising: a diphosphate synthase or prenyltransferase, and a Nudix hydrolase of the mevalonate pathway; or diphosphate synthase or isopentenyl transferase, Nudix hydrolase of the mevalonate pathway, and geranyl synthase (GES) of the terpene synthase pathway; or diphosphate synthase or isopentenyl transferase of the mevalonate pathway and GES of the terpene synthase pathway.

28. The engineered fusion protein of claim 27, wherein the diphosphate synthase or isopentenyl transferase is located downstream of the Nudix hydrolase.

29. The engineered fusion protein of claim 27 or 28, wherein the GES is located between the diphosphate synthase and the Nudix hydrolase or between the isopentenyl transferase and the Nudix hydrolase.

30. The engineered fusion protein according to any one of claims 27-29, further comprising one or more linker sequences, wherein the one or more linker sequences are located between the Nudix hydrolase and the diphosphate synthase or isopentenyl transferase of the fusion protein; wherein the linker is connected to the C-terminus of the Nudix hydrolase and the N-terminus of the diphosphate synthase or isopentenyl transferase; wherein, The sequence of the linker comprises the sequence shown in SEQ ID NO:17 or SEQ ID NO:

18.

31. A method for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, comprising culturing the host cell of any one of claims 1-26 in a culture medium, wherein the culture medium comprises an inducing agent and at least one carbon substrate.

32. The method according to claim 31, wherein the inducing agent is lactose or IPTG, and wherein the at least one carbon substrate is selected from the group consisting of glucose, glycerol, lactose, sucrose, and combinations thereof.

33. A kit for producing geraniol, geranyl acetate, or geraniol and geranyl acetate, wherein the kit comprises the host cell of any one of claims 1-26 and instructions for use.

34. The kit of claim 33, wherein the host cells are dissolved in solution or lyophilized.

35. The kit of claim 34, wherein the host cells are preserved by deep freezing.

Citation Information

Cited By

  • Method for improving geraniol tolerance of escherichia coli and application thereof

    CN120249343A